Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost

Severe influenza is marked by an excessive immune response, which can cause considerable damage to the lungs and affect other organs. This uncontrolled reaction often leads to hospitalisation due to

Jeremy Skillington, the CEO of Poolbeg Pharma, will be presenting at the Cell & Gene Therapy International Europe 2024 event. His presentation will focus on a novel approach using p38

The landscape of drug discovery has long been known for its complexity and the substantial time and financial resources required to bring a single drug to the market. Traditional methods,

Poolbeg Pharma plc is a biopharmaceutical company dedicated to developing and commercialising innovative medicines that address significant unmet medical needs. The company actively seeks partners for its pipeline of ground-breaking

Liam Tremble, Principal Scientist at Poolbeg Pharma, is deeply involved in developing innovative treatments for diseases with significant unmet medical needs. His current work spans oncology, infectious diseases, and endocrinology,

The medtech industry is at a crucial point, experiencing significant growth driven by the Covid-19 pandemic, which spurred a wave of innovation and investment. Though the sector has now returned

University College Dublin (UCD) has been recognised for leading the way in research collaboration with industry in Ireland, according to Knowledge Transfer Ireland’s latest Annual Knowledge Transfer Survey (AKTS) for

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost